BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape

BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape

In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF sequencing approaches, and unmet needs. The BRAFV600E mutation confers constitutive activity of the MAPK pathway, leading to enhanced growth, proliferation, and survival of tumor cells. Testing for BRAF mutations enables patients to be treated with therapies …

Personalized Therapy, Surgical Staging, and Expanded Screening Guidelines Drive Progress in NSCLC

Isabel Preeshagul, DO, MBS, discusses the need for a nuanced approach when selecting between targeted therapies in ALK- and EGFR-altered NSCLC.